CliffBio
small molecule

CUBICIN

DAPTOMYCIN

Loss of exclusivity—loss of exclusivity
CompanyCubist Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameCUBICIN
Active ingredientDAPTOMYCIN
Strength250MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalSeptember 2003
Marketing statusDISCN

More from Cubist Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

CUBICIN patent cliff — loss of exclusivity — | CliffBio